Psychiatr. praxi. 2023;24(2):123-130

Sekvenční léčba schizofrenie

MUDr. Josef Višňovský
Klinika psychiatrie, FN Olomouc

Na 65. česko­‑slovenské psychofarmakologické konferenci v Mariánských Lázních se uskutečnilo sympozium firmy Angelini zaměřené na sekvenční léčbu schizofrenie.

Accepted: May 31, 2023; Published: June 13, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Višňovský J. Sekvenční léčba schizofrenie. Psychiatr. praxi. 2023;24(2):123-130.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Levitan B, Markowitz M, Mohamed AF, et al. Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment. Psychiatr Serv. 2015 Jul;66(7):719-26. doi: 10.1176/appi.ps.201400188. Epub 2015 Mar 16. PMID: 25772762. Go to original source... Go to PubMed...
    2. Achtyes E, Simmons A, Skabeev A, et al. Patient preferences concerning the efficacy and side­‑effect profile of schizophrenia medications: a survey of patients living with schizophrenia. BMC Psychiatry. 2018 Sep 12;18(1):292. doi: 10.1186/s12888-018-1856-y. PMID: 30223804; PMCID: PMC6142379. Go to original source... Go to PubMed...
    3. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double­‑blind, placebo- and olanzapine­‑controlled study. Am J Psychiatry. 2011 Sep;168(9):957-67. doi: 10.1176/appi.ajp.2011.10060907. Epub 2011 Jun 15. PMID: 21676992. Go to original source... Go to PubMed...
    4. Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open­‑label, extension study. J Clin Psychiatry. 2013 May;74(5):507-15. doi: 10.4088/JCP.12m08084. Epub 2013 Mar 13. PMID: 23541189. Go to original source... Go to PubMed...
    5. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta­‑analysis. Lancet Psychiatry. 2020 Jan;7(1):64-77. doi: 10.1016/S2215-0366(19)30416-X. Epub 2019 Dec 17. PMID: 31860457; PMCID: PMC7029416. Go to original source... Go to PubMed...
    6. Mattingly GW, Haddad PM, Tocco M, et al. Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open­‑label study. BMC Psychiatry. 2020 May 5;20(1):199. doi: 10.1186/s12888-020-02523-1. PMID: 32370778; PMCID: PMC7201608. Go to original source... Go to PubMed...
    7. Huhn M, Nikolakopoulou A, Schneider­‑Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi­‑episode schizophrenia: a systematic review and network meta­‑analysis. Lancet. 2019 Sep 14;394(10202):939-951. doi: 10.1016/S0140-6736(19)31135-3. Epub 2019 Jul 11. Erratum in: Lancet. 2019 Sep 14;394(10202):918. PMID: 31303314; PMCID: PMC6891890. Go to original source... Go to PubMed...
    8. Abosi O, Lopes S, Schmitz S, Fiedorowicz JG. Cardiometabolic effects of psychotropic medications. Horm Mol Biol Clin Investig. 2018 Jan 10;36(1):/j/hmbci.2018. 36. issue-1/hmbci-2017-0065/hmbci-2017-0065.xml. doi: 10.1515/hmbci-2017-0065. PMID: 29320364; PMCID: PMC6818518. Go to original source... Go to PubMed...
    9. Nicol GE, Kolko R, Lenze EJ, et al. Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic­‑Treated Youth: A Randomized Pilot Study. J Child Adolesc Psychopharmacol. 2019 Aug;29(6):439-447. doi: 10.1089/cap.2018.0120. Epub 2019 Apr 17. PMID: 30994376; PMCID: PMC6661918. Go to original source... Go to PubMed...
    10. McWhinney S, Kolenic M, Franke K, et al. Obesity as a Risk Factor for Accelerated Brain Ageing in First­‑Episode Psychosis­‑A Longitudinal Study. Schizophr Bull. 2021 Oct 21;47(6):1772-1781. doi: 10.1093/schbul/sbab064. PMID: 34080013; PMCID: PMC8530396. Go to original source... Go to PubMed...
    11. Siafis S, Davis JM, Leucht S. Antipsychotic drugs: from 'major tranquilizers' to Neuroscience­‑based­‑Nomenclature. Psychol Med. 2021 Feb;51(3):522-524. doi: 10.1017/S0033291719003957. Epub 2020 Jan 8. PMID: 31910928. Go to original source... Go to PubMed...
    12. Baldez DP, Biazus TB, Rabelo­‑da­‑Ponte FD, et al. The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta­‑analyses of randomized controlled trials. Neurosci Biobehav Rev. 2021 Jul;126:265-275. Go to original source...
    13. Harvey PD, Siu CO, Ogasa M, Loebel A. Effect of lurasidone dose on cognition in patients with schizophrenia: post­‑hoc analysis of a long­‑term, double­‑blind continuation study. Schizophr Res. 2015 Aug;166(1-3):334-8 Go to original source...
    14. Hagi K, Nosaka T, Dickinson D, et al. Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia: A Systematic Review and Meta­‑analysis. JAMA Psychiatry. 2021 May 1;78(5):510-518. doi: 10.1001/jamapsychiatry.2021.0015. PMID: 33656533; PMCID: PMC7931134. Go to original source... Go to PubMed...
    15. Pochiero I, Calisti F, Comandini A, et al. Impact of Lurasidone and Other Antipsychotics on Body Weight: Real­‑World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia. Int J Gen Med. 2021 Jul 31;14:4081-4094. Go to original source...
    16. Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open­‑label, extension study. J Clin Psychiatry. 2013 May;74(5):507-15. Go to original source...
    17. Mattingly GW, Haddad PM, Tocco M, et al. Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open­‑label study. BMC Psychiatry. 2020 May 5;20(1):199. Go to original source...
    18. Etchecopar­‑Etchart D, Korchia T, Loundou A, et al. Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta­‑Analysis. Schizophr Bull. 2021 Mar 16;47(2):298-308. Go to original source... Go to PubMed...
    19. Huhn M, Nikolakopoulou A, Schneider­‑Thoma J, et al. Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi­‑Episode Schizophrenia: A Systematic Review and Network Meta­‑Analysis. Focus (Am Psychiatr Publ). 2020 Oct;18(4):443-455. Go to original source...
    20. Gregory A, Mallikarjun P, Upthegrove R. Treatment of depression in schizophrenia: systematic review and meta­‑analysis. Br J Psychiatry. 2017 Oct;211(4):198-204. Go to original source... Go to PubMed...
    21. Tiihonen J, Tanskanen A, Taipale H. 20-Year Nationwide Follow­‑Up Study on Discontinuation of Antipsychotic Treatment in First­‑Episode Schizophrenia. Am J Psychiatry. 2018 Aug 1;175(8):765-773. Go to original source... Go to PubMed...
    22. Ostuzzi G, Vita G, Bertolini F, et al. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia­‑spectrum disorders who are clinically stable: a systematic review and network meta­‑analysis. Lancet Psychiatry. 2022 Aug;9(8):614-624. Go to original source...
    23. Liu CC, Takeuchi H. Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose­‑Reduction Algorithm. CNS Drugs. 2020 Feb;34(2):117-126. doi: 10.1007/s40263-019-00682-8. PMID: 31741178. Go to original source... Go to PubMed...
    24. Thornicroft G, Tansella M, Antonelli R. The Lancet Mortality in schizophrenia: a meta-analysis. 2005;365(9460):589-599.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.